prikaz prve stranice dokumenta miRNA in prostate cancer: challenges toward translation
  Download
PDF 1.64 MB
Scientific paper - Original scientific paper
miRNA in prostate cancer: challenges toward translation
Epigenomics, 12 (2020), 6; 543-558. https://doi.org/10.2217/epi-2019-0275
Abramović, Irena; Ulamec, Monika; Ana, Katušić Bojanac; Bulić-Jakuš, Floriana; Ježek, Davor; Sinčić, Nino

Cite this document

Abramović, I., Ulamec, M., Ana, K. B., Bulić Jakuš, F., Ježek, D. & Sinčić, N. (2020). miRNA in prostate cancer: challenges toward translation. Epigenomics, 12. (6), 543-558. doi: 10.2217/epi-2019-0275

Abramović, Irena, et al. "miRNA in prostate cancer: challenges toward translation." Epigenomics, vol. 12, no. 6, 2020, pp. 543-558. https://doi.org/10.2217/epi-2019-0275

Abramović, Irena, Monika Ulamec, Katušić Bojanac Ana, Floriana Bulić Jakuš, Davor Ježek and Nino Sinčić. "miRNA in prostate cancer: challenges toward translation." Epigenomics 12, no. 6 (2020): 543-558. https://doi.org/10.2217/epi-2019-0275

Abramović, I., et al. (2020) 'miRNA in prostate cancer: challenges toward translation', Epigenomics, 12(6), pp. 543-558. doi: 10.2217/epi-2019-0275

Abramović I, Ulamec M, Ana KB, Bulić Jakuš F, Ježek D, Sinčić N. miRNA in prostate cancer: challenges toward translation. Epigenomics [Internet]. 2020 March [cited 2024 November 17];12(6):543-558. doi: 10.2217/epi-2019-0275

I. Abramović, M. Ulamec, K. B. Ana, F. Bulić Jakuš, D. Ježek and N. Sinčić, "miRNA in prostate cancer: challenges toward translation", Epigenomics, vol. 12, no. 6, pp. 543-558, March 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:146208. [Accessed: 17 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)miRNA in prostate cancer: challenges toward translation
AuthorIrena Abramović
AuthorMonika Ulamec
AuthorKatušić Bojanac Ana
AuthorFloriana Bulić-Jakuš
AuthorDavor Ježek
AuthorNino Sinčić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Histology and Embryology)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Medical Biology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Cytology, Histology and Embryology
Abstract (english)
Prostate cancer (PCa) represents the most commonly diagnosed neoplasm among men. miRNAs, as biomarkers, could further improve reliability in distinguishing malignant versus nonmalignant, and aggressive versus nonaggressive PCa. However, conflicting data was reported for certain miRNAs, and there was a lack of consistency and reproducibility, which has been attributed to diverse (pre)analytical factors. In order to address current challenges in miRNA clinical research on PCa, a PubMed-based literature search was conducted with the last update in May 2019. After identifying critical variations in designs and protocols that undermined clear-cut evidence acquisition, and reliable translation into clinical practice, we propose guidelines for most critical steps that should be considered in future research of miRNA as biomarkers, especially in PCa.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleEpigenomics
Numberingvol. 12, no. 6, pp. 543-558
p-ISSN1750-1911
e-ISSN1750-192X
DOIhttps://doi.org/10.2217/epi-2019-0275
URN:NBNurn:nbn:hr:105:146208
Publication2020-03
Document URLhttps://www.futuremedicine.com/doi/10.2217/epi-2019-0275
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2021-04-16 08:49:37